دورية أكاديمية
Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection.
| العنوان: | Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection. |
|---|---|
| المؤلفون: | Lyke KE; Center for Vaccine Development and Division of Malaria Research, Institute for Global Health, University of Maryland School of Medicine, Baltimore, MD 21201., Ishizuka AS; Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892., Berry AA; Center for Vaccine Development and Division of Malaria Research, Institute for Global Health, University of Maryland School of Medicine, Baltimore, MD 21201., Chakravarty S; Sanaria Inc., Rockville, MD 20850., DeZure A; Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892., Enama ME; Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892., James ER; Sanaria Inc., Rockville, MD 20850., Billingsley PF; Sanaria Inc., Rockville, MD 20850., Gunasekera A; Sanaria Inc., Rockville, MD 20850., Manoj A; Sanaria Inc., Rockville, MD 20850., Li M; Sanaria Inc., Rockville, MD 20850.; Protein Potential LLC, Rockville, MD 20850., Ruben AJ; Sanaria Inc., Rockville, MD 20850., Li T; Sanaria Inc., Rockville, MD 20850., Eappen AG; Sanaria Inc., Rockville, MD 20850., Stafford RE; Sanaria Inc., Rockville, MD 20850.; Protein Potential LLC, Rockville, MD 20850., Kc N; Sanaria Inc., Rockville, MD 20850.; Protein Potential LLC, Rockville, MD 20850., Murshedkar T; Sanaria Inc., Rockville, MD 20850., Mendoza FH; Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892., Gordon IJ; Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892., Zephir KL; Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892., Holman LA; Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892., Plummer SH; Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892., Hendel CS; Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892., Novik L; Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892., Costner PJ; Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892., Saunders JG; Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892., Berkowitz NM; Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892., Flynn BJ; Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892., Nason MC; Biostatistics Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892., Garver LS; Entomology Branch, Walter Reed Army Institute of Research, Silver Spring, MD 20910., Laurens MB; Center for Vaccine Development and Division of Malaria Research, Institute for Global Health, University of Maryland School of Medicine, Baltimore, MD 21201., Plowe CV; Center for Vaccine Development and Division of Malaria Research, Institute for Global Health, University of Maryland School of Medicine, Baltimore, MD 21201., Richie TL; Sanaria Inc., Rockville, MD 20850., Graham BS; Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892., Roederer M; Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892., Sim BK; Sanaria Inc., Rockville, MD 20850.; Protein Potential LLC, Rockville, MD 20850., Ledgerwood JE; Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892., Hoffman SL; Sanaria Inc., Rockville, MD 20850., Seder RA; Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892; rseder@mail.nih.gov. |
| المصدر: | Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2017 Mar 07; Vol. 114 (10), pp. 2711-2716. Date of Electronic Publication: 2017 Feb 21. |
| نوع المنشور: | Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural |
| اللغة: | English |
| بيانات الدورية: | Publisher: National Academy of Sciences Country of Publication: United States NLM ID: 7505876 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1091-6490 (Electronic) Linking ISSN: 00278424 NLM ISO Abbreviation: Proc Natl Acad Sci U S A Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Washington, DC : National Academy of Sciences |
| مواضيع طبية MeSH: | Malaria Vaccines/*administration & dosage , Malaria, Falciparum/*prevention & control , Plasmodium falciparum/*drug effects , Vaccines, Attenuated/*administration & dosage, Adolescent ; Adult ; Female ; Healthy Volunteers ; Humans ; Malaria Vaccines/adverse effects ; Malaria Vaccines/immunology ; Malaria, Falciparum/immunology ; Malaria, Falciparum/parasitology ; Male ; Middle Aged ; Plasmodium falciparum/pathogenicity ; Sporozoites/immunology ; Sporozoites/pathogenicity ; T-Lymphocytes/drug effects ; T-Lymphocytes/immunology ; T-Lymphocytes/parasitology ; Vaccines, Attenuated/adverse effects ; Vaccines, Attenuated/immunology |
| مستخلص: | A live-attenuated malaria vaccine, Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers sterile protection against controlled human malaria infection (CHMI) with Plasmodium falciparum (Pf) parasites homologous to the vaccine strain up to 14 mo after final vaccination. No injectable malaria vaccine has demonstrated long-term protection against CHMI using Pf parasites heterologous to the vaccine strain. Here, we conducted an open-label trial with PfSPZ Vaccine at a dose of 9.0 × 10 5 PfSPZ administered i.v. three times at 8-wk intervals to 15 malaria-naive adults. After CHMI with homologous Pf parasites 19 wk after final immunization, nine (64%) of 14 (95% CI, 35-87%) vaccinated volunteers remained without parasitemia compared with none of six nonvaccinated controls ( P = 0.012). Of the nine nonparasitemic subjects, six underwent repeat CHMI with heterologous Pf7G8 parasites 33 wk after final immunization. Five (83%) of six (95% CI, 36-99%) remained without parasitemia compared with none of six nonvaccinated controls. PfSPZ-specific T-cell and antibody responses were detected in all vaccine recipients. Cytokine production by T cells from vaccinated subjects after in vitro stimulation with homologous (NF54) or heterologous (7G8) PfSPZ were highly correlated. Interestingly, PfSPZ-specific T-cell responses in the blood peaked after the first immunization and were not enhanced by subsequent immunizations. Collectively, these data suggest durable protection against homologous and heterologous Pf parasites can be achieved with PfSPZ Vaccine. Ongoing studies will determine whether protective efficacy can be enhanced by additional alterations in the vaccine dose and number of immunizations. |
| References: | Immunity. 2016 Oct 18;45(4):889-902. (PMID: 27692609) Science. 1987 Jun 26;236(4809):1661-6. (PMID: 3299700) Am J Trop Med Hyg. 1990 Nov;43(5):441-5. (PMID: 2240371) Am J Trop Med Hyg. 1986 Jan;35(1):66-8. (PMID: 3511753) Emerg Infect Dis. 2005 Mar;11(3):436-41. (PMID: 15757560) Nat Med. 2016 Jun;22(6):614-23. (PMID: 27158907) J Infect Dis. 2009 Aug 1;200(3):337-46. (PMID: 19569965) J Infect Dis. 2002 Apr 15;185(8):1155-64. (PMID: 11930326) J Infect Dis. 2001 Feb 15;183(4):640-7. (PMID: 11170991) JCI Insight. 2017 Jan 12;2(1):e89154. (PMID: 28097230) Vaccine. 2015 Nov 27;33 Suppl 4:D13-23. (PMID: 26324116) Vaccine. 2015 Dec 22;33(52):7452-61. (PMID: 26469720) Malar J. 2013 Oct 29;12:376. (PMID: 24168370) N Engl J Med. 2015 Nov 19;373(21):2025-37. (PMID: 26488565) Am J Trop Med Hyg. 2010 Aug;83(2):258-65. (PMID: 20682864) Hum Vaccin. 2010 Jan;6(1):97-106. (PMID: 19946222) PLoS One. 2010 Oct 21;5(10):e13490. (PMID: 21042404) Lancet. 2012 Feb 4;379(9814):413-31. (PMID: 22305225) N Engl J Med. 1997 Jan 9;336(2):86-91. (PMID: 8988885) Science. 2013 Sep 20;341(6152):1359-65. (PMID: 23929949) Am J Trop Med Hyg. 1993 Aug;49(2):166-73. (PMID: 8357078) Nature. 1987 Dec 17-23;330(6149):664-6. (PMID: 3120015) Immunity. 2008 May;28(5):710-22. (PMID: 18468462) Nat Commun. 2014 Jun 13;5:4052. (PMID: 24923250) PLoS One. 2015 May 01;10(5):e0124243. (PMID: 25933168) Nat Commun. 2013;4:2836. (PMID: 24284865) Trans R Soc Trop Med Hyg. 1984;78(3):339-41. (PMID: 6380022) Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6055-60. (PMID: 23530242) Science. 2011 Oct 28;334(6055):475-80. (PMID: 21903775) PLoS One. 2012;7(2):e31247. (PMID: 22355349) J Immunol. 2008 Jan 1;180(1):64-71. (PMID: 18097005) Lancet. 2015 Jul 4;386(9988):31-45. (PMID: 25913272) Nat Med. 2016 Apr;22(4):433-8. (PMID: 26901407) Proc Natl Acad Sci U S A. 1988 Jan;85(2):573-6. (PMID: 2963334) N Engl J Med. 2009 Jul 30;361(5):468-77. (PMID: 19641203) Proc Natl Acad Sci U S A. 2013 May 7;110(19):7862-7. (PMID: 23599283) PLoS Pathog. 2011 Dec;7(12):e1002389. (PMID: 22144890) Lancet. 2011 May 21;377(9779):1770-6. (PMID: 21514658) |
| معلومات مُعتمدة: | R44 AI058499 United States AI NIAID NIH HHS; R44 AI058375 United States AI NIAID NIH HHS; R44 AI055229 United States AI NIAID NIH HHS; T32 GM007171 United States GM NIGMS NIH HHS; K23 AI125720 United States AI NIAID NIH HHS |
| فهرسة مساهمة: | Keywords: T-cell immunology; live-attenuated vaccine; malaria; plasmodium; sporozoite |
| المشرفين على المادة: | 0 (Malaria Vaccines) 0 (Vaccines, Attenuated) |
| تواريخ الأحداث: | Date Created: 20170223 Date Completed: 20180418 Latest Revision: 20181113 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC5347610 |
| DOI: | 10.1073/pnas.1615324114 |
| PMID: | 28223498 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1091-6490 |
|---|---|
| DOI: | 10.1073/pnas.1615324114 |